The function of CD164 in breast cancer and its possibility as a molecular biomarker: bioinformatics analysis and experimental validation
Frontiers in Immunology · 2025
DOI: 10.3389/fimmu.2025.1601547 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, 2025. Verfasst von Mengxin Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, Antigens, CD. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Breast cancer is the most prevalent malignancy among women globally. Molecular-targeted therapy improves treatment efficacy by precisely targeting tumor-specific molecules, minimizing damage to healthy tissues. Identifying new molecular targets is essential for enhancing therapeutic outcomes and prognosis in breast cancer.
Methods
The TCGA database was used to assess CD164 expression in breast cancer and its correlation with prognosis. Chemosensitivity analysis was performed to evaluate the association between CD164 and response to targeted therapies. Immune infiltration analysis was conducted to assess the relationship between CD164 expression and immune cell populations. CCK-8 assays, clonogenic assays, and flow cytometry analyses were employed to examine the effects of CD164 knockdown on cell viability, proliferation, cell cycle progression, and apoptosis. RNA sequencing and Gene Set Enrichment Analysis (GSEA) were performed to identify pathways regulated by CD164.
Results
CD164 was highly expressed in breast cancer tissues and correlated with poorer prognosis, including shorter disease-free and overall survival. Chemosensitivity analysis linked CD164 to sensitivity to multiple targeted therapies, suggesting its role in oncogenic pathways. Immune infiltration analysis revealed CD164’s association with immunosuppressive cells, including resting CD4 memory T cells, M2 macrophages, and mast cells, while exhibiting a negative correlation with Tregs and NK cells, underscoring its significance in the immunosuppressive tumor microenvironment. CD164 knockdown inhibited cell viability and proliferation and induced cell cycle arrest and apoptosis. RNA sequencing and GSEA showed that CD164 regulates proliferation, metabolism, migration, and adhesion pathways while suppressing tumor-promoting pathways and activating immune-related pathways.
Conclusions
CD164 plays a critical role in breast cancer progression, influencing tumor growth, immune evasion, and therapeutic response. It represents a promising therapeutic target, offering potential for improving breast cancer treatment and prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, China.
- Department of Biomedical Science, College of Basic Medical Sciences, Jilin University, Changchun, China.
Zitieren
APA
Li, M., Mao, J., Wang, G., Chen, J., Hong, J., Wang, X., Liang, B., & Song, D. (2025). The function of CD164 in breast cancer and its possibility as a molecular biomarker: bioinformatics analysis and experimental validation. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1601547
Vancouver
Li M, Mao J, Wang G, Chen J, Hong J, Wang X, et al. The function of CD164 in breast cancer and its possibility as a molecular biomarker: bioinformatics analysis and experimental validation. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1601547
BibTeX
@article{Li2025,
author = {Li, Mengxin and Mao, Juanjuan and Wang, Guang and Chen, Jiasi and Hong, Jinghui and Wang, Xue and Liang, Baoling and Song, Dong},
title = {The function of CD164 in breast cancer and its possibility as a molecular biomarker: bioinformatics analysis and experimental validation},
journal = {Frontiers in Immunology},
year = {2025},
doi = {10.3389/fimmu.2025.1601547}
}
EUVIMED